Mesa Laboratories Stock Price, News & Analysis

Mesa Laboratories reported robust financial results for 3Q22, with a 60% increase in revenues to $54,696 and a 31% increase for the nine months to $125,456 compared to last year. However, the company faced an operating loss of $(2,512), a significant decline from a profit of $22 in 3Q21. Despite this, non-GAAP adjusted operating income rose 73% for the quarter, reflecting strong organic growth of 12%. The company emphasized its strategic acquisition of Agena Bioscience and further growth in its biopharmaceutical and clinical genomics sectors, signaling positive long-term prospects.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a quarterly dividend of $0.16 per share, payable on March 15, 2022, to shareholders of record by February 28, 2022. Mesa is recognized as a leader in providing life science tools and quality control solutions in the pharmaceutical and healthcare sectors. The company emphasizes ensuring product integrity and enhancing safety for patients and workers globally. This announcement reflects Mesa's commitment to returning value to shareholders despite the ongoing uncertainties in the market.

Mesa Laboratories, Inc. (NASDAQ:MLAB) reported its financial results for 2Q22, highlighting a revenue increase of 12% to $35,840 thousands, while net income rose 39% to $3,720 thousands or $0.70 per diluted share. However, operating income decreased 6% to $4,201 thousands. For the six months, revenues grew 14% to $70,760 thousands, with net income climbing 47% to $5,715 thousands or $1.07 per diluted share. The company attributed the growth to strong performance in sterilization and disinfection, although it faced challenges in the Instruments division due to supply chain issues.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has appointed Shiraz Ladiwala to its Board of Directors as of October 28, 2021. Ladiwala, a former leader at Thermo Fisher Scientific, has extensive experience in corporate strategy and operations with a focus on the Asia/Pacific region. His addition brings the board to eight members, with six being independent. The chairman, John Sullivan, emphasized Ladiwala's international expertise, which is expected to support Mesa's strategic objectives and mission to enhance safety and quality in life sciences.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has successfully completed the acquisition of Agena Biosciences, Inc. This strategic move aims to enhance Mesa's growth in the life sciences tools market, with expectations that over 90% of future revenues will derive from biopharma, medical devices, and healthcare services. Agena is projected to add $63M to $67M in revenue within the first year, with a significant portion expected to be recurring. The acquisition positions Mesa to benefit from high single-digit organic revenue growth and strengthens its global presence.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, set to be paid on December 15, 2021. Shareholders must be on record by November 30, 2021. Mesa is a leading provider of quality control solutions across pharmaceutical, healthcare, and medical device sectors, with products segmented into four divisions aimed at ensuring safety and quality in these industries. The company cautions that future performance may be influenced by various risks including market demand fluctuations and economic uncertainties.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced its acquisition of Agena Bioscience, Inc. for $300 million, expected to close by December 31, 2021. This all-cash transaction will be financed by cash on hand and credit facilities. Agena, known for its molecular diagnostics tools, is projected to add $63-$67 million in revenues in the first year, with approximately 65% being recurring. The acquisition is expected to enhance Mesa's capabilities in clinical genomics, providing innovative solutions for personalized treatment.

Mesa Laboratories reported a strong 1Q22, with revenues increasing 17% year-over-year to $34,920,000. However, operating income fell 13% to $3,123,000. Net income surged 64% to $1,995,000, translating to $0.38 per diluted share. Adjusted operating income rose 12% to $9,136,000, reflecting strong performance in the Sterilization and Disinfection Control segment. The company noted a gross profit percentage decline of 430 bps to 64% overall. CEO Gary Owens expressed optimism about growth opportunities despite economic uncertainties linked to COVID and inflation.

Mesa Laboratories, Inc. (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, payable on September 15, 2021, to shareholders of record by the close of business on August 31, 2021. Mesa Labs specializes in quality control solutions across various sectors including pharmaceutical and healthcare. Their mission is to enhance product integrity and safety by offering services through four divisions. The company advises caution as actual results may differ due to risks highlighted in their forward-looking statements.